Gaetani, Lorenzo
Höglund, Kina
Parnetti, Lucilla
Pujol-Calderon, Fani
Becker, Bruno
Eusebi, Paolo
Sarchielli, Paola
Calabresi, Paolo
Di Filippo, Massimiliano
Zetterberg, Henrik
Blennow, Kaj
Funding for this research was provided by:
Vetenskapsrådet
European Research Council
Torsten Söderbergs Stiftelse
Knut och Alice Wallenbergs Stiftelse
Swedish State Support for Clinical Research
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Alzheimerfonden
Article History
Received: 12 November 2017
Accepted: 8 January 2018
First Online: 23 January 2018
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki and was approved by the regional ethical committee. All participants provided written informed consent to participate in the study.
: LG received travel grants from Biogen-Idec, Biogen, Novartis, Teva, Genzyme, and Almirall to attend national and international conferences. PC received research support from Bayer Schering, Biogen-Dompé, Boehringer Ingelheim, Eisai, Lundbeck, Merck-Serono, Novartis, Sanofi-Aventis, Sigma-Tau, and UCB Pharma. MDF participated in advisory boards of Biogen Idec, Teva, and Bayer, received travel grants from Bayer Schering, Biogen-Dompé, Biogen-Idec, Merck-Serono, Novartis, and Sanofi-Aventis to attend national and international conferences, and speaker and writing honoraria from Biogen Idec, Novartis, and Sanofi-Genzyme. HZ has served on advisory boards for Eli Lilly, Roche Diagnostics, and Pharmasum Therapeutics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. KB has served as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.